Mesoblast - ADR Peer Comparison
$17.44
$-0.74
(-4.07%)
As on 28-Aug-2026 16:00EDT
Market cap
$2,262 Mln
Revenue (TTM)
$65 Mln
P/E Ratio
--
P/B Ratio
4.1
Div. Yield
0 %
Edit
| Mesoblast - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
2,262 | 2,928 | 2,152 | 851 | 828 |
Revenue ($ Mln) |
65 | 450 | 549 | -- | 366 |
Net Profit ($ Mln) |
-94.37 | -188.21 | 17.88 | -175.85 | 9.27 |
Net Margin (%) |
-144.33 | -41.86 | 3.26 | -- | 2.53 |
RoE (%) |
-16.10 | -28.46 | 1.43 | -106.84 | 3.39 |
Price to Earnings |
-- | -- | 123.80 | -- | 83.57 |
Price-To-Book |
4.15 | 4.96 | 1.71 | 5.68 | 3.10 |
Income Statement ($ Mln)
| Mesoblast - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
120.25 | -- | -- | -- | -- |
|
Cost of Revenue
|
16.67 | -- | -- | -- | -- |
|
Gross Profit
|
103.58 | -- | -- | -- | -- |
|
Operating Expenses
|
171.50 | -- | -- | -- | -- |
|
Operating Profit (EBIT)
|
-51.25 | -- | -- | -- | -- |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
-56.89 | -- | -- | -- | -- |
|
Provision for Tax
|
-- | -- | -- | -- | -- |
|
Profit after Tax (Net Income)
|
-57.50 | -- | -- | -- | -- |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | -- | -- | -- | -- |
Liabilities ($ Mln)
| Mesoblast - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
568.41 | -- | -- | -- | -- |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
123.56 | -- | -- | -- | -- |
|
Current Liabilities
|
81.11 | -- | -- | -- | -- |
|
Total Liabilities
|
773.08 | -- | -- | -- | -- |
Assets ($ Mln)
| Mesoblast - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
575.59 | -- | -- | -- | -- |
|
Current Assets
|
197.49 | -- | -- | -- | -- |
|
Total Assets
|
-- | -- | -- | -- | -- |
|
Total Debt*
|
-- | -- | -- | -- | -- |
|
Net Current Assets
|
116.38 | -- | -- | -- | -- |
Cashflow ($ Mln)
| Mesoblast - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-- | -- | -- | -- | -- |
|
Cash Flow from Investing Activities
|
-- | -- | -- | -- | -- |
|
Cash from Financing Activities
|
-15.33 | -- | -- | -- | -- |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Mesoblast - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
-8.89 | -- | -- | -- | -- |
|
ROE (%)
|
-9.86 | -- | -- | -- | -- |
|
ROA (%)
|
-7.38 | -- | -- | -- | -- |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-47.82 | -- | -- | -- | -- |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Mesoblast - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
5.99 | -- | -- | -- | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
43.71 | -- | -- | -- | -- |
|
EPS Growth (%)
|
0.45 | -- | -- | -- | -- |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Mesoblast - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-30.40 | -- | -- | -- | -- |
|
Price / Book Value
|
3.08 | -- | -- | -- | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-- | -- | -- | -- | -- |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Mesoblast - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-- | -- | -- | -- | -- |
|
Short term debt to equity ratio
|
-- | -- | -- | -- | -- |
|
Current Ratio
|
2.43 | -- | -- | -- | -- |
|
Quick Ratio
|
2.09 | -- | -- | -- | -- |
|
Interest Coverage
|
-- | -- | -- | -- | -- |
Operating Efficiency Ratios
| Mesoblast - ADR | Zai Lab - ADR | HUTCHMED (China) - ADR | DBV Technologies S.A. - ADR | Pharming Group N.V. ADS each representing 10 (PHAR) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
47.46 | -- | -- | -- | -- |
|
Asset Turnover
|
0.15 | -- | -- | -- | -- |
|
Receivable days
|
109.26 | -- | -- | -- | -- |
|
Inventory Days
|
551.78 | -- | -- | -- | -- |
|
Payable days
|
587.20 | -- | -- | -- | -- |
|
Cash Conversion Cycle
|
73.83 | -- | -- | -- | -- |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
